Related Experiment Video
Updated: Dec 24, 2025
Maintaining Human Glioblastoma Cellular Diversity Ex vivo using Three-Dimensional Organoid Culture
Published on: August 25, 2022
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2
Christine E Eyler1, Qiulian Wu, Kenneth Yan
1Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Abstract:
Malignant gliomas are aggressive brain tumors with limited therapeutic options, and improvements in treatment require a deeper molecular understanding of this disease. As in other cancers, recent studies have identified highly tumorigenic subpopulations within malignant gliomas, known generally as cancer stem cells. Here, we demonstrate that glioma stem cells (GSCs) produce nitric oxide via elevated nitric oxide synthase-2 (NOS2) expression. GSCs depend on NOS2 activity for growth and tumorigenicity, distinguishing them from non-GSCs and normal neural progenitors. Gene expression profiling identified many NOS2-regulated genes, including the cell-cycle inhibitor cell division autoantigen-1 (CDA1). Further, high NOS2 expression correlates with decreased survival in human glioma patients, and NOS2 inhibition slows glioma growth in a murine intracranial model. These data provide insight into how GSCs are mechanistically distinct from their less tumorigenic counterparts and suggest that NOS2 inhibition may be an efficacious approach to treating this devastating disease.
Insights
Glioma stem cells (GSCs) rely on nitric oxide synthase-2 (NOS2) for growth and tumor formation. Inhibiting NOS2 may offer a new therapeutic strategy for aggressive malignant gliomas.
Area of Science:
- Neuro-oncology
- Cancer Biology
- Molecular Medicine
Background:
- Malignant gliomas are aggressive brain tumors with poor prognoses.
- Cancer stem cells (CSCs) drive tumor growth and recurrence in various cancers, including gliomas.
- Understanding the unique molecular mechanisms of glioma stem cells (GSCs) is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the role of nitric oxide synthase-2 (NOS2) in the biology and tumorigenicity of GSCs.
- To identify molecular pathways regulated by NOS2 in GSCs.
- To evaluate NOS2 inhibition as a potential therapeutic strategy for malignant gliomas.
Main Methods:
- Quantification of nitric oxide production and NOS2 expression in GSCs.
- Functional assays assessing GSC growth and tumorigenicity under NOS2 inhibition.
- Gene expression profiling to identify NOS2-regulated genes.
- Correlation analysis of NOS2 expression with patient survival data.
- Evaluation of NOS2 inhibition in an in vivo murine glioma model.
Main Results:
- Glioma stem cells (GSCs) exhibit elevated nitric oxide synthase-2 (NOS2) expression and nitric oxide production.
- GSCs demonstrate a dependency on NOS2 activity for their growth and tumorigenic potential.
- NOS2 regulates key genes, including cell division autoantigen-1 (CDA1), involved in cell-cycle control.
- High NOS2 expression in human gliomas correlates with reduced patient survival.
- Inhibition of NOS2 significantly slows glioma growth in a preclinical mouse model.
Conclusions:
- Glioma stem cells (GSCs) possess distinct molecular dependencies, including reliance on NOS2.
- NOS2 activity is critical for maintaining GSC growth and tumorigenicity.
- Targeting NOS2 represents a promising therapeutic avenue for treating malignant gliomas.
